SlideShare a Scribd company logo
Professional and Business
Ethics in Health Care
Background
 Medical professional is facing a decreasing
professionalism and increasing ethical problems
around the globe
 Charles Dougherty:
 “General features of the pervasive hold of
commercialism in medicine include an increase in
competition and decline in professionalism among
physicians, a view of health care as commodity and
patients as consumers, and a general
depersonalization of doctor-patient relationship
including dilution of the tradition of physician as
patient advocate”
HOW CAN WE EXPLAIN THIS PHENOMENA?
FIRST: The Theory of Market
 Developed by Adam Smith:
 Economic man, self-interested, and fundamentally
asocial, motivated by an insatiable desire to improve
his material condition, is the model that explains
human motivation and action
 The special characteristics of healthcare market is
both Private as well as Social/Public domain
 Therefore, health care business is unique. It must
balance the obligation to care for others with the
necessity of making a profit as a business.
Patient
Care
Profit
Making
What is profitable to Businesses in
the Healthcare industry:
Selling Medicine/Drugs
Selling Medical Supplies
Hospital equipment
Lab equipment
Selling Medical Services
Patient care
Nursing home care
Home care
New Health Care Technology
Market Driven Care
Advantage
Incentive for
innovation
Incentive for
efficiency
Less government
intervention
Disadvantage
 Alienate physicians
 Undermine patient
trust of physicians
 Hurt academic medical
centers and the
research establishment
 More patients without
health care coverage.
Public Cost of Poor Health
1. Higher disease burden
2. Longer time to recover from sickness
3. Shorter time to work (become
productive –economically and
socially)
4. Lower life expectancy
What is not as directly
profitable is:
Prevention
“An ounce of prevention is
worth a pound of cure”
But companies can’t make much money from preventing
diseases
Therefore, healthcare should be managed by the “people”
and “for the people”
How Market Driven Healthcare
Cuts Costs
recruit the healthiest patients
excluding the sickest
rationing care by making it inconvenient to
obtain
denying care by a variety of mechanisms.
Physicians’ Dilemma in Market
Driven Healthcare
As Caregiver:
 provide a wide range of services,
recommend the best treatments
 improve patients' quality of life
As Efficiently keeping expenses to a
minimum:
 limit the use of services
 increase efficiency
 shorten the time spent with each patient
 use specialists sparingly
Second: Stakeholder Theory:
Who are the
Stakeholders for a
Healthcare
Organization?
From Pat Werhane: “Business Ethics, Stakeholder Theory, and the Ethics of Healthcare in Organizations”
The Investor: Pharmaceutical
Industries
 The pharmaceutical industry in 2006 was worth US$ 643
billion.
 Total pharmaceutical sales from the top 10 companies
accounted for more than 40% of the total market (see
table).
Pharmaceutical Industry as
Investors
Irrational Use of
Drugs
 In 2005, the Indian National
Commission on Macroeconomics
and Health labeled 10 out of 25
top selling brands of medicines in
the country as being either
“irrational or non-essential or
hazardous.”
Pharmaceutical Industry as
Investors
Questionable New Drugs
 A survey in April 2005 by the French journal La Revue
Prescribe concluded that 68 per cent of the 3,096 new
products approved in France between 1981 and 2004
brought “nothing new” to existing treatments.
 A breakdown of more than 1,000 new drugs approved by
the US Food and Drug Administration between 1989 and
2000 revealed that more than three-quarters had no
therapeutic benefit over existing products.
Pharmaceutical Industry as
Investors
Advertising with Incomplete Information
 2005 study of Psychobiology of the Paulista Medical
School of the Federal University of São Paulo Brazil
 Analysed 24 Brazilian advertisements for the same
psychoactive drugs as advertised in American and/or
British publications from the same period.
 Observed that “Brazilian advertisements omitted
information on usage restrictions, such as
contraindications, adverse reactions, interactions,
warnings and precautions, and that such information
was present in American and British advertisements.”
How They Do It? --- Drug
Promotion is the Key
1. Increasing the perceived frequency
and/or severity of the indications.
2. Widening the indications to include
more people.
3. Increasing the perceived likelihood and
magnitude of benefits.
4. Decreasing the perceived likelihood and
magnitude of harms.
5. Increasing the use of the drug for longer
durations.
Doctors’ Biased Behavior
Evidence shows that biased doctors are more likely to:
1. Prescribe a drug if they had recently attended a sponsored
event by the manufacturer.
2. Prescribe a drug that is not clinically indicated.
3. Have a drug placed on a hospital formulary.
*Governments’ Key
Recommendations:
1. Implement, improve and monitor legislation in line
with the WHO Resolution on the Rational Use of
Medicines and the WHO Ethical Criteria for Medicinal
Drug Promotion.
2. Support the provision of independent information on
drugs for consumers and health professionals.
3. Implement and enforce a ban on gifts to doctors.
4. Enforce strict sanctions that will deter poor corporate
practice in drug promotion.
5. Take measures to improve the transparency of drug
companies’ marketing activities and seriously address
the conflict of interest encountered in drug companies’
funding of medical education.
**Key Recommendations at the
Company Level:
1. Stop the practice of gifts to doctors
2. Implement rigorous policies on vetting of drug
promotion materials and adherence to existing codes
of conduct
3. Provide transparent and verifiable information
on the precise nature of relationships and associated
funding for all stakeholder groups, including health
professionals, pharmacists, students, journalists,
clinical research organizations and patient groups.
**Industry-Wide Level:
1. Ensure codes of conduct on drug promotion
extend to interactions with health professionals AND
consumers.
2. Invest in innovative partnerships with
government and civil society organizations so
that corporate funding of disease awareness
campaigns, and CME may be channeled via blind
trusts in line with specific health priorities of
consumers at a community or national level.
Bibliography
 Drugs, Doctors and Dinners: How drug companies influence
health in the developing world
 Managed Care and the Morality of the Marketplace
(NEJM, 333:50-52, 7/6, 1995)
How to maintain the
humanitarian aspects of health
care?
Professionalism and ethics are the key to maintain
humanitarian aspects of health care
How to Execute Ethical Principles in
an Organization?
Organizational
Goals
The
Stakeholder
Analysis
Approach
Ethical
Justifiabl
Decision
Organizational Goals Approach
 Institutional mission statements are commonly expressed
the development and implementation of organizational
goals
 An ethical analysis of organization behavior can be
conceived as a means of ensuring that an appropriate
mission statement is adopted, kept up date, and put into
effect
 The J&J case (1982) – “a 350 words credo”
“First, responsibility of the company is to healthcare
professionals and customers who use its products”
 Useless mission statement:
“To improve the total health of our communities, working in
partnership with the people we serve”
 A hospital has ethical responsibilities deriving from its
organizational roles as employer and business entity
 Institution
 Its physician
 Other care givers
 Employers
 Individual patients and families
 Community as a whole
The Woodstock Ethical
Framework
 Compassion and respect for human dignity
 Commitment to professional competence
 Commitment to a spirit of service
 Honesty
 Confidentiality
 Good stewardship and careful administration
Stakeholder Analysis
 “Any group or individual who can affect or is affected by the
corporation” (Evan and Freeman, 1988:100)
 Primary stakeholders: groups whose continued participation
is necessary to the survival of the organization (e.g.
shareholders, employees, customers, suppliers, creditors,
and governments)
 Secondary stakeholders: groups whose participation is not
essential to the organization, although they are affected by
organizational activities (e.g. media, community, and other
business)

More Related Content

PPTX
Ethics from a Pharmaceutical Industry Perspective
PDF
Navigating the Ethical Compass Unraveling Business Ethics in Healthcare.pdf
PPTX
Ethical issues during interaction with the industry!
PPTX
Pharma Final Presentation
PPTX
Pharma Final Presentation
PPTX
The Aequitas Group Capabilities Overview Q409
PDF
Ethics And The Business Of Biomedicine 1st Edition Denis G Arnold Editor
PDF
Ethical issues in healthcare marketing**
Ethics from a Pharmaceutical Industry Perspective
Navigating the Ethical Compass Unraveling Business Ethics in Healthcare.pdf
Ethical issues during interaction with the industry!
Pharma Final Presentation
Pharma Final Presentation
The Aequitas Group Capabilities Overview Q409
Ethics And The Business Of Biomedicine 1st Edition Denis G Arnold Editor
Ethical issues in healthcare marketing**

Similar to Ethics-1 and business in public health.pptx (20)

PPTX
Csr astrazeneca
PPT
Finding the Right Care for the Right Price, Cost and Quality (Geof Baker)
PPTX
Market Access 101: Connecting Access Challenges to Brand Opportunities
PDF
Healthcare Sector Analysis PowerPoint Presentation Slides
PPTX
Medical Ethics
PPSX
Ethics for medical student
PPT
Collusive_Behaviour_Medicines_and_Access.ppt
PPTX
HCAD 650 Healthcare Ethics
PPTX
Hcad 650 healthcare ethics
PPTX
Ethical & unethical pharma market
PPTX
Highlights from ExL Pharma's 2nd Pharmaceutical Managed Markets
PPTX
healthcaresectoranalysispowerpointpresentationslides-190410093536.pptx
PDF
PA Healthcare Forum Insights
PPTX
Health service management (1)
PPTX
ethical promotion of drugs.pptx
PPTX
Ethical promotion of drugs
PDF
Understanding Patient Rights and Ethics_ A Comprehensive Guide.pdf
PPTX
Medical ethics
PDF
Partners in healthcare
PPT
Effective Patient Support Globally
Csr astrazeneca
Finding the Right Care for the Right Price, Cost and Quality (Geof Baker)
Market Access 101: Connecting Access Challenges to Brand Opportunities
Healthcare Sector Analysis PowerPoint Presentation Slides
Medical Ethics
Ethics for medical student
Collusive_Behaviour_Medicines_and_Access.ppt
HCAD 650 Healthcare Ethics
Hcad 650 healthcare ethics
Ethical & unethical pharma market
Highlights from ExL Pharma's 2nd Pharmaceutical Managed Markets
healthcaresectoranalysispowerpointpresentationslides-190410093536.pptx
PA Healthcare Forum Insights
Health service management (1)
ethical promotion of drugs.pptx
Ethical promotion of drugs
Understanding Patient Rights and Ethics_ A Comprehensive Guide.pdf
Medical ethics
Partners in healthcare
Effective Patient Support Globally
Ad

More from EmanZayed17 (20)

PPTX
Case of laryngeal carcinoma for total laryngectomy
PPTX
Case of myoepithelial carcinoma tumor ppt
PPTX
One Case presentation of laryngeal cancer.
PPTX
wageeh TL clinical case report. ....pptx
PPTX
Case report laryngeal cancer.... .pptx.
PPT
Ears, anatomy and otoscopic pathology, pictures and diagrams.ppt
PPTX
Elhayany clincal case report ca larynx.pptx
PPTX
Head And Neck Scientific Meeting1.pptx
PPT
Benign Thyroid-Y6.ppt
PPTX
caudal devation correction.pptx
PPTX
Elsayed Mokhtar case presentation
PPTX
glossopharyngealnerve-170429133151.pptx
PPTX
Mohamed.pptx
PPTX
Fibrous dysplasia.pptx
PPTX
ahmed ali.pptx
PPTX
nasalpolyps-151224095805.pptx
PPTX
diseases of pharynx.pptx
PPTX
Rhinitis.pptx
PPTX
malignant sinonasal tumors+management.pptx
PPTX
Biologics.pptx
Case of laryngeal carcinoma for total laryngectomy
Case of myoepithelial carcinoma tumor ppt
One Case presentation of laryngeal cancer.
wageeh TL clinical case report. ....pptx
Case report laryngeal cancer.... .pptx.
Ears, anatomy and otoscopic pathology, pictures and diagrams.ppt
Elhayany clincal case report ca larynx.pptx
Head And Neck Scientific Meeting1.pptx
Benign Thyroid-Y6.ppt
caudal devation correction.pptx
Elsayed Mokhtar case presentation
glossopharyngealnerve-170429133151.pptx
Mohamed.pptx
Fibrous dysplasia.pptx
ahmed ali.pptx
nasalpolyps-151224095805.pptx
diseases of pharynx.pptx
Rhinitis.pptx
malignant sinonasal tumors+management.pptx
Biologics.pptx
Ad

Recently uploaded (20)

PPTX
CARDIOVASCULAR AND RENAL DRUGS.pptx for health study
PPTX
Hearthhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh
PDF
OSCE Series ( Questions & Answers ) - Set 6.pdf
PPTX
09. Diabetes in Pregnancy/ gestational.pptx
PPT
Rheumatology Member of Royal College of Physicians.ppt
PPTX
Wheat allergies and Disease in gastroenterology
PPTX
y4d nutrition and diet in pregnancy and postpartum
PDF
MNEMONICS MNEMONICS MNEMONICS MNEMONICS s
PPT
Dermatology for member of royalcollege.ppt
PDF
OSCE SERIES ( Questions & Answers ) - Set 5.pdf
PDF
Comparison of Swim-Up and Microfluidic Sperm Sorting.pdf
PDF
SEMEN PREPARATION TECHNIGUES FOR INTRAUTERINE INSEMINATION.pdf
PPTX
Human Reproduction: Anatomy, Physiology & Clinical Insights.pptx
PPTX
Reading between the Rings: Imaging in Brain Infections
PPTX
NRP and care of Newborn.pptx- APPT presentation about neonatal resuscitation ...
PDF
Plant-Based Antimicrobials: A New Hope for Treating Diarrhea in HIV Patients...
PPTX
Acute Coronary Syndrome for Cardiology Conference
PPTX
Neoplasia III.pptxjhghgjhfj fjfhgfgdfdfsrbvhv
PPTX
Approach to chest pain, SOB, palpitation and prolonged fever
PDF
Transcultural that can help you someday.
CARDIOVASCULAR AND RENAL DRUGS.pptx for health study
Hearthhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh
OSCE Series ( Questions & Answers ) - Set 6.pdf
09. Diabetes in Pregnancy/ gestational.pptx
Rheumatology Member of Royal College of Physicians.ppt
Wheat allergies and Disease in gastroenterology
y4d nutrition and diet in pregnancy and postpartum
MNEMONICS MNEMONICS MNEMONICS MNEMONICS s
Dermatology for member of royalcollege.ppt
OSCE SERIES ( Questions & Answers ) - Set 5.pdf
Comparison of Swim-Up and Microfluidic Sperm Sorting.pdf
SEMEN PREPARATION TECHNIGUES FOR INTRAUTERINE INSEMINATION.pdf
Human Reproduction: Anatomy, Physiology & Clinical Insights.pptx
Reading between the Rings: Imaging in Brain Infections
NRP and care of Newborn.pptx- APPT presentation about neonatal resuscitation ...
Plant-Based Antimicrobials: A New Hope for Treating Diarrhea in HIV Patients...
Acute Coronary Syndrome for Cardiology Conference
Neoplasia III.pptxjhghgjhfj fjfhgfgdfdfsrbvhv
Approach to chest pain, SOB, palpitation and prolonged fever
Transcultural that can help you someday.

Ethics-1 and business in public health.pptx

  • 2. Background  Medical professional is facing a decreasing professionalism and increasing ethical problems around the globe  Charles Dougherty:  “General features of the pervasive hold of commercialism in medicine include an increase in competition and decline in professionalism among physicians, a view of health care as commodity and patients as consumers, and a general depersonalization of doctor-patient relationship including dilution of the tradition of physician as patient advocate” HOW CAN WE EXPLAIN THIS PHENOMENA?
  • 3. FIRST: The Theory of Market  Developed by Adam Smith:  Economic man, self-interested, and fundamentally asocial, motivated by an insatiable desire to improve his material condition, is the model that explains human motivation and action  The special characteristics of healthcare market is both Private as well as Social/Public domain  Therefore, health care business is unique. It must balance the obligation to care for others with the necessity of making a profit as a business.
  • 5. What is profitable to Businesses in the Healthcare industry: Selling Medicine/Drugs Selling Medical Supplies Hospital equipment Lab equipment Selling Medical Services Patient care Nursing home care Home care New Health Care Technology
  • 6. Market Driven Care Advantage Incentive for innovation Incentive for efficiency Less government intervention Disadvantage  Alienate physicians  Undermine patient trust of physicians  Hurt academic medical centers and the research establishment  More patients without health care coverage.
  • 7. Public Cost of Poor Health 1. Higher disease burden 2. Longer time to recover from sickness 3. Shorter time to work (become productive –economically and socially) 4. Lower life expectancy
  • 8. What is not as directly profitable is: Prevention “An ounce of prevention is worth a pound of cure” But companies can’t make much money from preventing diseases Therefore, healthcare should be managed by the “people” and “for the people”
  • 9. How Market Driven Healthcare Cuts Costs recruit the healthiest patients excluding the sickest rationing care by making it inconvenient to obtain denying care by a variety of mechanisms.
  • 10. Physicians’ Dilemma in Market Driven Healthcare As Caregiver:  provide a wide range of services, recommend the best treatments  improve patients' quality of life As Efficiently keeping expenses to a minimum:  limit the use of services  increase efficiency  shorten the time spent with each patient  use specialists sparingly
  • 11. Second: Stakeholder Theory: Who are the Stakeholders for a Healthcare Organization?
  • 12. From Pat Werhane: “Business Ethics, Stakeholder Theory, and the Ethics of Healthcare in Organizations”
  • 13. The Investor: Pharmaceutical Industries  The pharmaceutical industry in 2006 was worth US$ 643 billion.  Total pharmaceutical sales from the top 10 companies accounted for more than 40% of the total market (see table).
  • 14. Pharmaceutical Industry as Investors Irrational Use of Drugs  In 2005, the Indian National Commission on Macroeconomics and Health labeled 10 out of 25 top selling brands of medicines in the country as being either “irrational or non-essential or hazardous.”
  • 15. Pharmaceutical Industry as Investors Questionable New Drugs  A survey in April 2005 by the French journal La Revue Prescribe concluded that 68 per cent of the 3,096 new products approved in France between 1981 and 2004 brought “nothing new” to existing treatments.  A breakdown of more than 1,000 new drugs approved by the US Food and Drug Administration between 1989 and 2000 revealed that more than three-quarters had no therapeutic benefit over existing products.
  • 16. Pharmaceutical Industry as Investors Advertising with Incomplete Information  2005 study of Psychobiology of the Paulista Medical School of the Federal University of São Paulo Brazil  Analysed 24 Brazilian advertisements for the same psychoactive drugs as advertised in American and/or British publications from the same period.  Observed that “Brazilian advertisements omitted information on usage restrictions, such as contraindications, adverse reactions, interactions, warnings and precautions, and that such information was present in American and British advertisements.”
  • 17. How They Do It? --- Drug Promotion is the Key 1. Increasing the perceived frequency and/or severity of the indications. 2. Widening the indications to include more people. 3. Increasing the perceived likelihood and magnitude of benefits. 4. Decreasing the perceived likelihood and magnitude of harms. 5. Increasing the use of the drug for longer durations.
  • 18. Doctors’ Biased Behavior Evidence shows that biased doctors are more likely to: 1. Prescribe a drug if they had recently attended a sponsored event by the manufacturer. 2. Prescribe a drug that is not clinically indicated. 3. Have a drug placed on a hospital formulary.
  • 19. *Governments’ Key Recommendations: 1. Implement, improve and monitor legislation in line with the WHO Resolution on the Rational Use of Medicines and the WHO Ethical Criteria for Medicinal Drug Promotion. 2. Support the provision of independent information on drugs for consumers and health professionals. 3. Implement and enforce a ban on gifts to doctors. 4. Enforce strict sanctions that will deter poor corporate practice in drug promotion. 5. Take measures to improve the transparency of drug companies’ marketing activities and seriously address the conflict of interest encountered in drug companies’ funding of medical education.
  • 20. **Key Recommendations at the Company Level: 1. Stop the practice of gifts to doctors 2. Implement rigorous policies on vetting of drug promotion materials and adherence to existing codes of conduct 3. Provide transparent and verifiable information on the precise nature of relationships and associated funding for all stakeholder groups, including health professionals, pharmacists, students, journalists, clinical research organizations and patient groups.
  • 21. **Industry-Wide Level: 1. Ensure codes of conduct on drug promotion extend to interactions with health professionals AND consumers. 2. Invest in innovative partnerships with government and civil society organizations so that corporate funding of disease awareness campaigns, and CME may be channeled via blind trusts in line with specific health priorities of consumers at a community or national level.
  • 22. Bibliography  Drugs, Doctors and Dinners: How drug companies influence health in the developing world  Managed Care and the Morality of the Marketplace (NEJM, 333:50-52, 7/6, 1995)
  • 23. How to maintain the humanitarian aspects of health care? Professionalism and ethics are the key to maintain humanitarian aspects of health care
  • 24. How to Execute Ethical Principles in an Organization? Organizational Goals The Stakeholder Analysis Approach Ethical Justifiabl Decision
  • 25. Organizational Goals Approach  Institutional mission statements are commonly expressed the development and implementation of organizational goals  An ethical analysis of organization behavior can be conceived as a means of ensuring that an appropriate mission statement is adopted, kept up date, and put into effect  The J&J case (1982) – “a 350 words credo” “First, responsibility of the company is to healthcare professionals and customers who use its products”
  • 26.  Useless mission statement: “To improve the total health of our communities, working in partnership with the people we serve”  A hospital has ethical responsibilities deriving from its organizational roles as employer and business entity  Institution  Its physician  Other care givers  Employers  Individual patients and families  Community as a whole
  • 27. The Woodstock Ethical Framework  Compassion and respect for human dignity  Commitment to professional competence  Commitment to a spirit of service  Honesty  Confidentiality  Good stewardship and careful administration
  • 28. Stakeholder Analysis  “Any group or individual who can affect or is affected by the corporation” (Evan and Freeman, 1988:100)  Primary stakeholders: groups whose continued participation is necessary to the survival of the organization (e.g. shareholders, employees, customers, suppliers, creditors, and governments)  Secondary stakeholders: groups whose participation is not essential to the organization, although they are affected by organizational activities (e.g. media, community, and other business)